氟伐他汀等他汀类药物通过降低低密度脂蛋白水平减少心血管疾病风险的研究进展  

Research Progress on Fluvastatin and other Statins Lowering LDL-C to Reduce Cardiovascular Risk

作　　者：李琳 LI Lin(Department of Endocrinology,PLA Rocket Force Characteristic Medical Center,Beijing 100088,China)

机构地区：[1]中国人民解放军火箭军特色医学中心内分泌科,北京100088

出　　处：《药品评价》2020年第22期12-14,共3页Drug Evaluation

摘　　要：低密度脂蛋白胆固醇是心血管疾病的主要原因之一,现在有大量证据支持降低低密度脂蛋白胆固醇可以降低心血管疾病的发病率和死亡率。本文将综述关于低密度脂蛋白胆固醇作为心血管疾病的终身性危险因子和作为氟伐他汀等他汀类药物治疗靶点的研究进展。Low-density lipoprotein cholesterol(LDL-C)is one major cause of cardiovascular disease,and there is now overwhelming evidence to support lowering LDL-C to reduce cardiovascular morbidity and mortality.In this review,we summarizes on current developments in the understanding of LDL-C as lifelong risk factor and treatment targets to reduce cardiovascular risk by lowering LDL-C with fluvastatin and other statins,which are a class of drugs frequently prescribed to lower cholesterol.

关 键 词：氟伐他汀 低密度脂蛋白胆固醇 心血管疾病 

分 类 号：R972[医药卫生—药品]